Aromatase inhibitor-associated bone and musculoskeletal effects: new evidence defining etiology and strategies for management.
Aromatase inhibitors are widely used as adjuvant therapy in postmenopausal women with hormone receptor-positive breast cancer. While the agents are associated with slightly improved survival outcomes when compared to tamoxifen alone, bone and musculoskeletal side effects are substantial and often lead to discontinuation of therapy. Ideally, the symptoms should be prevented or adequately treated. This review will focus on bone and musculoskeletal side effects of aromatase inhibitors, including osteoporosis, fractures, and arthralgias. Recent advances have been made in identifying potential mechanisms underlying these effects. Adequate management of symptoms may enhance patient adherence to therapy, thereby improving breast cancer-related outcomes.
Duke Scholars
Altmetric Attention Stats
Dimensions Citation Stats
Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Tamoxifen
- Postmenopause
- Osteoporosis
- Oncology & Carcinogenesis
- Musculoskeletal System
- Humans
- Female
- Breast Neoplasms
- Bone and Bones
- Arthralgia
Citation
Published In
DOI
EISSN
Publication Date
Volume
Issue
Start / End Page
Location
Related Subject Headings
- Tamoxifen
- Postmenopause
- Osteoporosis
- Oncology & Carcinogenesis
- Musculoskeletal System
- Humans
- Female
- Breast Neoplasms
- Bone and Bones
- Arthralgia